Home＞BUSINESS
Meiji Grants Carbapenem Rights to Spero Outside Japan, Asia(Oct.13.2017)
Meiji Seika Pharma has sealed a licensing deal with Spero Therapeutics, granting the US biotech worldwide development and commercialization rights for tebipenem pivoxil, an oral form of a carbapenem-class antibiotic, excluding Japan and 13 Asian countries, the two companies said ...
(LOG IN FOR FULL STORY)
-
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected Apr.20
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers Apr.20
- Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup Apr.19
- Astellas Sells Agensys Research Facilities to Kite Apr.19
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit Apr.19
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says(Apr.20)
- Expert Cautions against Hasty Discussions on Cost Effective Assessments(Apr.20)
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)
